On February 11, 2022 Alligator reported that During the fourth quarter 2021 reached several key milestones in our pre-clinical, clinical, and partnered programs (Press release, Alligator Bioscience, FEB 11, 2022, View Source [SID1234608044]). Our priorities continue to be shaped by the rising need for cancer drug therapies that are safer and more effective."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Significant Events: October – December 2021
First patient dosed in the Phase II clinical trial of AC101 (HLX22), out-licensed to Shanghai Henlius Biotech, Inc. and AbClon, Inc.
Proof-of-concept Phase I clinical trial was initiated to assess the safety and efficacy of mitazalimab in combination with MesoPher, an experimental dendritic cell vaccine, in patients with pancreatic cancer, led by investigators at Erasmus MC University Medical Center Rotterdam, The Netherlands.
Alligator Bioscience and Aptevo Therapeutics co-authored a poster on ALG.APV-527, presented by Aptevo at SITC (Free SITC Whitepaper) Annual Meeting 2021.
Alligator presented three posters at the SITC (Free SITC Whitepaper) Annual Meeting 2021, on Neo-X-PrimeTM, ATOR-1017, and OPTIMIZE-1.
The company successfully carried out an oversubscribed Rights Issue raising approximately SEK 257 million, before transaction costs.
The company announced a trial update and early readout for ATOR-1017, confirming biomarker, safety, and tolerability data.
FINANCIAL SUMMARY
October-December 2021
Net sales, SEK 5.2 million (-)
Operating profit/loss, SEK -36.9 million (-34.1)
Profit/loss for the period, SEK -36.8 million (-34.5)
Earnings per share before and after dilution, SEK -0.17 (-0.48)
Cash flow for the period, SEK 198.8 million (-33.2)
Cash and cash equivalents, SEK 278.1 million (103.3)
January-December 2021
Net sales, SEK 12.9 million (4.4)
Operating profit/loss, SEK -141.6 million (-144.3)
Profit/loss for the period, SEK -141.7 million (-143.3)
Earnings per share before and after dilution, SEK -0.64 (-2.01)
Cash flow for the period, SEK 174.7 million (9.4)
Cash and cash equivalents, SEK 278.1 million (103.3)
The full report is attached as PDF available on the company’s website: View Source
Conference call/webcast
Alligator will host a conference call today, February 11, 2022, at 3:30 p.m. CEST for investors, analysts and media, where CEO Søren Bregenholt and CFO Marie Svensson will present and comment on the Interim Report. The conference call will be held in English.
The conference call will be broadcast live on the web and can be accessed via the link:
Alligator Bioscience, Audiocast with teleconference, Q4, 2021 | Financial Hearings
This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CEST on February 11, 2022.